NCT06106802 2026-02-23
Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment
Samsung Medical Center
Phase 2 Recruiting
Clinical Trials
12 trialsNCT06268210 2026-02-09
NeoLazer
Yonsei University
Phase 2 Recruiting
NCT05786430 2026-01-27
LUCAS
Yonsei University
Phase 2 Active not recruiting
NCT04965090 2025-12-18
A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT05299125 2025-10-01
AMIGO-1
Latin American Cooperative Oncology Group
Phase 2 Active not recruiting
NCT05338619 2023-09-01
PLATINUM
Korea University Guro Hospital
Phase 2 Unknown
NCT06020989 2023-09-01
CHAMELEON
Yonsei University
Phase 2 Unknown
NCT05716672 2023-02-08
Impact of Lazertinib Dose Modification on Effectiveness and Safety
Pusan National University Hospital
Unknown
NCT05701384 2023-01-27
Lazertinib 160mg in EGFR T790M NSCLC
Samsung Medical Center
Phase 2 Unknown
NCT05477615 2022-07-28
Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases
Seoul St. Mary's Hospital
Phase 2 Unknown
NCT05377788 2022-05-19
Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung Cancer
Samsung Medical Center
Unknown
NCT05167851 2021-12-22
The Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer
Yonsei University
Phase 2 Unknown